Table 4.

Atezolizumab based combinational therapy.

Cancer type	Treatment	Dose schedule	Efficacy	Adverse rate	Notes	References
NSCLC and SCLC	Atezolizumab + Chemotherapy	1200 mg A q3w + 6 mg/ml/min (AUC) carboplatin q3w + 100 mg/m² nab-paclitaxel q1w	18.6 months mOS	24% Serious TRAEs	NCT02367781 Patients with stage IV non-squamous NSCLC	(West et al., 2019)
		6 mg/ml/min (AUC) carboplatin q3w + 100 mg/m² nab-paclitaxel q1w for 4 or 6 21-day cycles, followed by maintenance therapy	13.9 months mOS	13% Serious TRAEs
	Atezolizumab + platinum-based doublet chemotherapy	15 mg/kg A + 6 mg/ml (AUC) carboplatin q3w + 200 mg/m2 paclitaxel q3w	36% ORR 12.9 months mOS	76% Grade≥3 TRAEs	NCT01633970 Patients with stage IIIB/IV NSCLC	(Markham, 2016; Liu et al., 2018)
		15 mg/kg A + 6 mg/ml (AUC) carboplatin q3w + 500 mg/m2 pemetrexed q3w	68% ORR 18.9 months mOS	52% Grade≥3 TRAEs
		15 mg/kg A + 6 mg/ml (AUC) carboplatin q3w + 100 mg/m2 nab-paclitaxel q1w	46% ORR 17 months mOS	89% Grade≥3 TRAEs
	Atezolizumab + Carboplatin and Etoposide	5 mg/ml/min (AUC) carboplatin for four 21-day cycles + 100 mg/m2 etoposide (D1-3 of each cycle) + 1200 mg A (D1 of each cycle)	60.2% ORR 12.3 months mOS	56.6% Grade 3/4 AEs	NCT02763579 Patients with extensive-stage SCLC	(Horn et al., 2018)
		5 mg/ml/min (AUC) carboplatin for four 21-day cycles + 100 mg/m2 etoposide (D1-3 of each cycle)	64.4% ORR 10.3 months mOS	56.1% Grade 3/4 AEs
Breast cancer	Atezolizumab ± nab-paclitaxel	840 mg A (D1 and 15) + 100 mg/m2 nab-paclitaxel (D1, 8, and 15) for 28-day cycle	56.0% ORR 21.3 months mOS	48.7% Grade 3/4 AEs	NCT02425891 Patients with metastatic TNBC	(Schmid et al., 2018)
		100 mg/m2 nab-paclitaxel (D1, 8, and 15) for 28-day cycle	45.9% ORR 17.6 months mOS	42.2% Grade 3/4 AEs